Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results